Symposia: Chronic Myeloid Leukemia: Clinical and Epidemiological
Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Research, Adult, Translational Research, Clinical Practice (Health Services and Quality), CML, Clinical Research, Health outcomes research, Chronic Myeloid Malignancies, Hematopoiesis, Diseases, Immune mechanism, Immunology, Real-world evidence, Biological Processes, Myeloid Malignancies, Molecular biology, Human, Measurable Residual Disease
Type: Oral
Hematology Disease Topics & Pathways:
Research, Adult, Translational Research, Clinical Practice (Health Services and Quality), CML, Clinical Research, Health outcomes research, Chronic Myeloid Malignancies, Hematopoiesis, Diseases, Immune mechanism, Immunology, Real-world evidence, Biological Processes, Myeloid Malignancies, Molecular biology, Human, Measurable Residual Disease
Monday, December 9, 2024: 4:30 PM-6:00 PM
Seaport Ballroom EFGH
(Manchester Grand Hyatt San Diego)
Moderators:
Thomas Ernst, MD, Jena University Hospital
and
Sarit E. Assouline, MD,
Disclosures:
No relevant conflicts of interest to declare.
This session will address laboratory predictors of response to therapy in chronic myeloid leukemia (CML). In addition to the role of BCR::ABL1 RQ-PCR monitoring, presenters will discuss the impact of mutations in other cancer related genes and the potential prognostic information to be gained from immunophenotyping and profiling, and circulating cytokines.
4:30 PM
4:45 PM
5:00 PM
5:15 PM
5:30 PM
5:45 PM
See more of: Oral and Poster Abstracts
*signifies non-member of ASH